Sfoglia per Autore  

Opzioni
Mostrati risultati da 21 a 40 di 123
Titolo Data di pubblicazione Autori Tipo File Abstract
The Combination of Everolimus and Low Dose Cyclosporine Allows Similar Results as the Standard Tacrolimus and MMF Regimen: 3-Year Results of a Prospective Clinical Trial in Renal Transplant Recipients 2010 Favi, Evaldo + Article (author) -
Lower Acute Rejection with Basiliximab and Short Course, Low Dose Thymoglobulin vs Basiliximab as Induction Therapy in Deceased Donor Renal Transplant Recipients: 6-Month Results of a Prospective Clinical Trial 2010 Evaldo Favi + Article (author) -
Once Daily Everolimus Is Safe and Effective in De Novo Renal Transplant Recipients: Six-Month Results of a Pilot Study 2010 Favi E. + Article (author) -
Significant improvement in patient survival after renal transplantation in the last decade 2011 Favi E. + Article (author) -
Metabolic syndrome and cardiovascular disease in kidney transplantation 2011 Favi E. + Article (author) -
Late Calcineurin Inhibitors Introduction after Induction with Basiliximab and Thymoglobulin Is Safe and Effective in Old for Old Renal Transplantation: 1-Year Results of a Prospective Clinical Study 2011 Favi, E. + Article (author) -
Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-Year results of a pilot study 2011 Favi E. + Article (author) -
Thymoglobulin and Basiliximab vs Basiliximab as Induction Therapy in Deceased Donor Kidney Transplantation: 1-Year Results of a Prospective Clinical Trial 2011 Favi, E. + Article (author) -
Induction with Thymoglobulin Plus Basiliximab Is Safe and Effective in Expanded Criteria Donor Kidney Transplant Recipients: 1-Year Results of a Prospective Clinical Trial 2012 Favi, E. + Article (author) -
Extended-release tacrolimus plus everolimus or micophenolate mofetil in deceased donor kidney transplant recipients : 6-month results of a prospective randomized clinical trial 2012 Favi, E. + Article (author) -
Extended-Release Tacrolimus Plus Everolimus vs Extended-Release Tacrolimus Plus Micophenolate Mofetil in Primary Deceased Donor Kidney Transplant Recipients: 1-Year Results of an Open Label, Randomized Phase 2 Clinical Trial 2013 Favi, E. + Article (author) -
The reduction of left ventricular hypertrophy after renal transplantation is not influenced by the immunosuppressive regimen 2013 Favi E. + Article (author) -
Mini-invasive living donor nephrectomy using the hand-assited laparoscopic technique: our first experience 2013 Favi, Evaldo + Article (author) -
ER-tacrolimus plus everolimus vs ER-tacrolimus plus MMF in primary deceased donor kidney transplantation: 1-year results of single center, open label, prospective, randomized clinical trial 2013 Favi, Evaldo + Article (author) -
Thymoglobulin plus basilixab versus basiliximab induction in deceased donor kidney transplant recipients treated with tacrolimus and: 1-year results of a prospective clinical trial 2013 Favi, Evaldo + Article (author) -
Thymoglobulin Plus Basiliximab vs Basiliximab as Induction Therapy in Deceased Donor Kidney Transplant Recipients Treated with Tacrolimus and Mycophenolate Mofetil: 1-Year Results of a Prospective Clinical Trial 2013 Favi, Evaldo + Article (author) -
Mini-invase living donor nephrectomy using the hand-assisted laparoscopic technique: our first experience 2013 Favi, Evaldo + Article (author) -
Hand-assisted laparoscopic nephrectomy for renal cell carcinoma in renal transplant recipients and patients with end-stage renal disease 2013 Favi, Evaldo + Article (author) -
Conversion from prograf to extended-release tacrolimus in stable kidney transplant recipients: better renal function after 3 year follow up 2013 Favi, Evaldo + Article (author) -
Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients : Three-yr results of a single-center prospective clinical trial 2013 Favi E. + Article (author) -
Mostrati risultati da 21 a 40 di 123
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile